Jury Awards Ariad $65.2M In Lilly Patent Feud

Law360 (May 4, 2006, 12:00 AM EDT) -- In the latest development in a long-running legal battle, a federal jury has awarded at least $65.2 million to Ariad Pharmaceuticals Inc. after finding that Eli Lilly and Co.’s osteoporosis drug Evista and septic shock drug Xigris infringed on an Ariad patent.

The patent at issue in the case, U.S. Patent No. 6,410,516, is owned by the Massachusetts Institute of Technology, the Whitehead Institute for Biomedical Research and the President and Fellows of Harvard College, and is licensed to Ariad.

Kineret is used to treat pain...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.